Related by context. All words. (Click for frequent words.) 74 HER2 negative 73 estrogen receptor ER 73 progesterone receptor negative 68 progesterone receptor PR 68 HER2 + 68 ERBB2 68 HER2 receptor 67 ErbB2 positive 67 estrogen receptor negative 67 hormone receptor negative 66 thyroglobulin 66 ERalpha 65 K ras mutations 65 progesterone receptor 65 mutated KRAS 65 Estrogen receptor 65 progesterone receptors 65 CD4 + CD# 65 HER-2/neu 65 p#HER# 65 Akt activation 65 carcinoembryonic antigen 64 epithelial tumors 64 estrogen progesterone 64 HER2 receptors 64 immunoreactivity 64 AGTR1 64 tumor histology 64 lactate dehydrogenase LDH 64 estrogen receptor positive 64 TNFalpha 64 cytokeratin 64 imatinib Gleevec 63 alkylating agents 63 HER2 63 colorectal carcinoma 63 mRNA expression 63 TOP2A 63 Ki# 63 histological subtype 63 breast carcinomas 63 mucinous 63 HER2 expression 63 LHRH receptor positive 63 castrate resistant 63 serum prostate 63 overexpress HER2 63 adriamycin 62 ovarian carcinoma 62 KRAS mutations 62 gemcitabine carboplatin 62 EGFR mutation positive 62 interleukin IL -# 62 HER2/neu 62 CD#c 62 cisplatin resistant 62 contralateral breast 62 HER2 ErbB2 62 lymphovascular invasion 62 c MYC 62 poorer prognosis 62 lymph node metastasis 62 Papillary 62 PSADT 62 Her2 62 mutant KRAS 62 NKG2D 62 Bleomycin 62 HER2 amplification 62 operable breast cancer 62 RASSF1A 62 IFN gamma 62 ERa 62 HER2 positive cancers 62 oral clodronate 62 hormone receptor positive 62 WT1 62 ERCC1 62 papillary thyroid carcinoma 61 isoenzyme 61 EGFR protein 61 syngeneic 61 Lenalidomide 61 IFN α 61 5FU 61 hepatocellular carcinomas 61 prostate carcinoma 61 glutamyl 61 tryptase 61 VEGFR1 61 dasatinib Sprycel 61 breast cancer TNBC 61 pancreatic lung 61 lumbar spine BMD 61 pmol L 61 prognostic indicator 61 androgen dependent 61 Trastuzumab 61 relapsed ovarian cancer 61 invasive ductal 61 TNF α 61 baseline LDH 61 hematological parameters 61 Adjuvant chemotherapy 61 factor receptor 61 estrogen receptor beta 61 locoregional recurrence 61 CagA 61 HER2 positive breast 61 nitrotyrosine 61 mutated K ras 61 colony stimulating factor 61 invasive lobular 61 pCR 61 HepG2 cells 61 Leydig cell 61 Estrogen Receptor 61 Ph + acute lymphoblastic 61 selective agonist 61 xenograft models 61 triiodothyronine 61 breast carcinoma 61 immunostaining 61 ALB # 61 prognostic factor 61 ErbB2 61 Cyclooxygenase 2 61 CD# + [001] 61 PDGFR alpha 61 Flu Cy 61 CR nPR 61 neoadjuvant chemotherapy 61 ER alpha 61 NMIBC 61 HER2 neu 61 estrogen receptor 61 Hcy 61 SPINK1 61 GSTP1 61 BRCA deficient 61 p# Shc 61 Neoadjuvant 61 paclitaxel cisplatin 61 Immunohistochemical staining 61 intravesical therapy 61 pancreatic endocrine 61 vWF 60 TGF ß 60 vimentin 60 p#NTR 60 resectable 60 grade cervical intraepithelial 60 pT3 60 CD# CD# 60 IDH1 mutation 60 Gleevec resistant 60 metastatic malignant 60 node metastases 60 plasmacytoid 60 antiproliferative effects 60 caveolin 1 60 TGFß 60 GSTT1 60 HER2 positive tumors 60 interleukin IL -6 60 cell acute lymphoblastic 60 constitutively active 60 immunohistochemical staining 60 atypical hyperplasia 60 taxane chemotherapy 60 Mutational 60 non mutated KRAS 60 GPNMB 60 EGFR inhibitors 60 pancreatic adenocarcinoma 60 inducible nitric oxide synthase 60 Factor Receptor 60 FLT3 60 selective modulator 60 PTPN# 60 FOLFOX6 60 CD#b 60 serous ovarian cancer 60 Erlotinib 60 colon carcinoma 60 ASCUS 60 urothelial carcinoma 60 hormone receptor status 60 TT genotype 60 Leukemias 60 HIF 1a 60 sarcomatoid 60 anti inflammatory cytokine 60 TGF β1 60 chlorambucil 60 serum TSH 60 Prostate specific antigen 60 taxane therapy 60 lymphoproliferative disorders 60 cyclin E 60 JAK2 V#F 60 5alpha reductase 60 completely resected 60 lymphocytosis 60 factor HGF 60 Hormone receptor 60 mouse xenograft models 60 Her2/neu 60 natriuretic peptides 60 Carcinoid tumors 60 progesterone receptor positive 60 cytokine signaling 60 Paraplatin ® 60 HER2 HER2 60 lymphomas leukemias 60 differentiated thyroid 60 5-FU/LV 60 BRAF V#E mutation 60 grade squamous intraepithelial 60 apolipoprotein B 60 imatinib therapy 60 tumor antigen 59 intima media thickness 59 platelet reactivity 59 Pharmacokinetics PK 59 HER2 positive metastatic breast 59 NQO1 59 gemcitabine Gemzar 59 GISTs 59 pegylated liposomal doxorubicin 59 KRAS wild 59 plasminogen activator inhibitor 59 somatostatin receptors 59 Partial Response 59 liver histology 59 HER2 positivity 59 CsA 59 IGFBP 59 IL 1ß 59 unconjugated 59 Basal Cell 59 etoposide 59 chemosensitivity 59 mesothelin 59 osteosarcomas 59 radiosensitivity 59 imatinib resistant 59 K + ATPase 59 overexpress 59 LHRH agonists 59 selectively inhibited 59 epithelial ovarian 59 metastatic gastric 59 adenocarcinomas 59 EGFR mutation 59 gastric adenocarcinoma 59 advanced adenomas 59 antiangiogenic therapy 59 rheumatoid factor 59 p# mutation 59 CIN3 59 HOXB# 59 Cytotoxic T 59 μg liter 59 CD4 + CD8 + 59 labetuzumab 59 MDA MB 59 bladder ovarian 59 CEACAM1 59 promoter methylation 59 constitutively expressed 59 HBsAg 59 5 HT2A serotonin 59 TNF blocker therapy 59 demonstrated antitumor activity 59 hA# 59 ERK1 2 59 EGFR expression 59 colorectal pancreatic 59 gefitinib Iressa 59 colorectal carcinomas 59 haematologic 59 invasive lobular carcinoma 59 Her2 positive 59 chronic eosinophilic leukemia 59 deletion 5q 59 log# copies mL 59 leukaemias 59 lymphopenia 59 IGF1R 59 Her-2/neu 59 PAM4 59 tumor suppressive 59 serum albumin 59 Gefitinib 59 Pemetrexed 59 B7 H3 59 Pegylated Interferon 59 VCAM 1 59 B7 H4 59 liver metastasis 59 Adjuvant Treatment 59 effector function 59 isoprostane 59 TIMP 1 59 IGF IR 59 oncoprotein 59 p# deficient 59 poly ADP ribose polymerase 59 eosinophil count 59 EGFR 59 EpCAM 59 VEGF receptor 59 natriuretic peptide 59 lactate dehydrogenase 59 locoregional 59 Fludarabine 59 gene polymorphism 59 doublet chemotherapy 59 HLA A2 59 lobular carcinomas 59 Doxil ® 59 bronchial epithelial cells 59 echocardiographic parameters 59 inhibitor COX 59 immunoreactive 59 Irinotecan 59 Metastatic 59 nanomolar 59 unresectable tumors 59 relapsed refractory 59 CXCR4 expression 59 MLH1 59 lobular involution 59 gastrointestinal stromal tumors 59 activating mutation 59 lobular carcinoma 59 FUSILEV enhances 59 micrometastasis 59 Akt signaling 59 whose tumors overexpress 59 pheochromocytomas 59 nonmetastatic 58 neoplastic 58 CCL# 58 cell adhesion molecule 58 6 mercaptopurine 58 alkaline phosphatase 58 CYP#A# substrate 58 SGPT 58 hormone LHRH 58 tumors GIST 58 heparanase 58 stage IIIb IV 58 refractory NSCLC 58 F FDG PET 58 hypereosinophilic syndrome 58 CYP#A# CYP#D# 58 squamous cell carcinoma SCC 58 mRCC 58 haematopoietic 58 SUVmax 58 TGF ß1 58 #.#ng/ml 58 preoperative PSA 58 breast cancer subtypes 58 microvessel density 58 grade gliomas 58 TNFa 58 leukemia multiple myeloma 58 trans retinoic acid 58 refractory metastatic 58 LPS induced 58 Herceptin trastuzumab 58 fulvestrant 58 BRAF V#E 58 CD3 + 58 survivin expression 58 IL6 58 TrkA 58 endocrine therapy 58 imatinib Gleevec ® 58 MDM2 58 panitumumab Vectibix 58 aromatase 58 receptor blocker 58 nodal metastasis 58 xenograft tumors 58 p# MAPK 58 tumor xenografts 58 PSA nadir 58 immunohistochemical analysis 58 IGFBP 3 58 MMP9 58 histologic subtypes 58 Tie2 58 monocyte chemoattractant protein 58 FDG uptake 58 idarubicin 58 pDCs 58 TGF beta1 58 myelodysplastic myeloproliferative diseases 58 BCL2 58 malignant prostate 58 biochemical recurrence 58 CR CRu 58 Decitabine 58 lymphoblasts 58 hepatocellular 58 SLNB 58 radiotherapy RT 58 HBeAg negative 58 EGFr 58 HER2 positive 58 HLA DR4 immune 58 baseline HbA1c 58 alanine aminotransferase ALT 58 activin 58 thyroid peroxidase 58 hTERT 58 Heterozygous 58 Î ² 58 nmol liter 58 recurrent glioblastoma multiforme 58 FasL 58 homozygotes 58 dehydroepiandrosterone sulfate 58 p# activation 58 FGFR3 58 normal karyotype 58 transgene expression 58 MAGE A3 58 p#Kip# 58 CD# expression [001] 58 T#I [002] 58 EphB4 58 hepatoma 58 E selectin 58 biochemical relapse 58 FLT3 ITD 58 castration resistant 58 epirubicin 58 inhibin 58 luminal 58 ALDH 58 beta subunit 58 small lymphocytic lymphoma 58 ABCB1 58 % CI #.#-#.# [007] 58 estrone 58 preoperative chemotherapy 58 nonalcoholic steatohepatitis NASH 58 cytolytic 58 Prognostic significance 58 PCA3 scores 58 HER2 overexpression 58 III EGFRvIII 58 relapsed MM 58 HBeAg 58 Foxp3 58 chemoresistant 58 hypogonadal 58 TNFα 58 cell adhesion molecules 58 recurrent NSCLC 58 cytologically 58 CHOP chemotherapy 58 mitoxantrone 58 CD# expression [002] 58 CD8 + 58 lung ovary 58 interferon pathway 58 uM 58 VEGF expression 58 luteinizing hormone releasing 58 malignant cancerous 58 BRCA1 BRCA2 58 FOLFIRI alone 58 ADAM# 58 μg ml 58 E cadherin expression 58 P selectin 58 ^ sup #m 58 EGFR mutant 58 colorectal adenocarcinoma 58 paclitaxel carboplatin 58 antibody titer 58 erlotinib Tarceva ® 58 bladder carcinoma 58 seminomas 58 ligand TRAIL 58 troponin T 57 colorectal gastric 57 mutant p# 57 cTnI 57 PCa 57 situ CIS 57 transaminases 57 mycophenolate mofetil 57 carboplatin paclitaxel 57 thyrotropin 57 cetuximab Erbitux R 57 PECAM 1 57 elevated triglyceride levels 57 mTOR mammalian target 57 metastatic melanomas 57 metastatic renal cell carcinoma 57 TIMP 57 HGPIN 57 atypical ductal hyperplasia 57 EGFRvIII 57 hormonal therapies 57 FGFR1 57 ritonavir boosted 57 monocytic 57 scintigraphic 57 osteoblastic 57 sFlt 1 57 homodimers 57 BRAF mutation 57 pAkt 57 Estradiol 57 57 alveolar epithelial cells 57 pertuzumab 57 prognostic marker 57 myeloid 57 CK MB 57 myeloid cells 57 HLA DR2 57 KRAS mutation 57 anaplastic 57 relapsed SCLC 57 RRM1 57 neutrophil counts 57 cyclin dependent kinase inhibitor 57 standard chemotherapy regimens 57 Bezielle 57 p# antigen 57 Th2 57 gene amplification 57 extracapsular extension 57 MnSOD 57 malignant ovarian 57 NKX#.# 57 peritoneal carcinomatosis 57 Peginterferon alfa 2b 57 induced apoptosis 57 Tumor Necrosis Factor 57 androgen receptor AR 57 F FLT 57 ErbB1 57 CDK4 57 lymphocyte count 57 pulmonary metastases 57 μmol L 57 IL#B 57 Th2 cytokines 57 mutated p# 57 previously untreated follicular 57 androgen independent 57 CIN2 + 57 adjuvant radiotherapy 57 angiotensin converting enzyme 57 BRCA1 mutation carriers 57 CYT# potent vascular disrupting 57 pT2 57 adrenoceptor 57 wildtype 57 GFAP 57 tertile 57 CYP #D# 57 Th1 57 KRAS oncogene 57 cyclic AMP cAMP 57 atypia 57 leukemia AML 57 HER1 57 papillary 57 lymphocytic 57 metastatic malignant melanoma 57 AMACR 57 Estrogen receptor positive 57 CLL cells 57 transfected 57 MMP2 57 androgenic 57 TACE 57 PDGF receptor 57 bleomycin 57 cyclooxygenase 57 invasive carcinoma 57 metastatic colorectal 57 thromboxane A2 57 Notch1 57 cathepsins 57 castration resistant hormone refractory 57 lymph node metastases 57 PC3 cells 57 ovarian endometrial 57 paricalcitol 57 Prognostic factors 57 BRCA2 carriers 57 EGFR receptor 57 serum creatinine levels 57 GLI1 57 malignant ascites 57 MSH2 57 Monocyte 57 ERK activation 57 hypermethylated 57 Vidaza azacitidine 57 pg ml 57 Leukotriene 57 Anaplastic 57 1α 57 MEK1 57 tHcy 57 IL 1beta 57 antigen PSA levels 57 lysyl oxidase 57 CD#L 57 uterine cervix 57 FGFR4 57 dasatinib Sprycel ® 57 prostate cancer CaP 57 E cadherin 57 alanine aminotransferase 57 TGF β 57 intact parathyroid hormone 57 pro angiogenic 57 c MET 57 fludarabine cyclophosphamide 57 Squamous cell 57 inhibiting tumor 57 relapsed acute myelogenous 57 ApoB 57 distant metastasis 57 iNOS 57 metaglidasen 57 induces apoptosis 57 cytopenias 57 hCG beta 57 pathophysiological effects 57 TRAIL R2 57 interferon γ 57 neoplasias 57 CTNNB1 57 median PFS 57 -#.# log# 57 TRAIL R1 57 fallopian tube carcinoma 57 HBeAg seroconversion 57 inhibit EGFR 57 TTR gene 57 hepatic lipase 57 Acute myeloid leukemia 57 uPAR 57 chimeric monoclonal antibody 57 epididymal 57 adenoma recurrence 57 ECOG PS 57 alpha folate receptor 57 erlotinib Tarceva 57 metastatic pancreatic 57 sorafenib Nexavar 57 squamous histology 57 gene polymorphisms 57 e antigen HBeAg 57 JAK STAT 57 tNOX 57 HER2 amplified 57 Rituxan rituximab 57 daunorubicin 57 histologically 57 Hurthle cell 57 pDC 57 Vincristine 57 hCG Beta 57 CD8 + cytotoxic 57 interferon IFN 57 HLA DRB1 * 57 beta1 integrin 57 metastatic lymph nodes 57 Imatinib 57 hamartomas 57 overexpressed 57 peripheral blood mononuclear 57 Carboplatin 57 advanced hepatocellular carcinoma 57 monocyte 57 azacytidine 57 KIT mutations 57 gastrointestinal stromal tumors GIST 57 chemokine receptor 57 pleomorphic 57 MDR1 57 doxorubicin 57 seminal vesicle invasion 57 TOP2A gene 57 tirofiban 57 regulated kinase 57 cyclin D1 57 COX2 57 serum urate levels 57 allelic variants 57 sUA 56 olmesartan 56 specific antigen PSA 56 MCF7 56 LHRH 56 colorectal liver metastases 56 Hazard Ratio 56 EBRT 56 HER2 protein 56 euthyroid 56 xenografts 56 LymphoStat B belimumab 56 NF kB pathway 56 Butyrate 56 monocyte chemotactic protein 56 chemotherapy docetaxel 56 histologic subtype 56 flavopiridol 56 precursor lesions 56 cranial irradiation 56 binds selectively 56 alkylating agent 56 MTHFR 56 Endometrial 56 del 5q 56 Chemoradiation 56 EGFR HER2 56 Overexpression 56 serum triglycerides 56 anaplastic astrocytoma AA 56 HIF 1alpha 56 B7 H1 56 T1c 56 chemo resistant 56 BPH benign prostatic 56 Epidermal Growth Factor Receptor 56 HLA DR 56 endocrine therapies 56 basal cell carcinoma BCC 56 PTEN protein 56 hypoxia inducible factor 56 gastric corpus 56 SOD2 gene 56 cytotoxic agents 56 ADPKD 56 survivin 56 vulvar intraepithelial neoplasia 56 hepatic metastases 56 K ras gene 56 refractory chronic lymphocytic 56 epithelial ovarian cancer 56 metastatic prostate 56 nilotinib Tasigna 56 CCR7 56 calcitriol 56 fallopian tube cancers 56 postoperative chemotherapy 56 neoadjuvant treatment 56 DFMO 56 cyclooxygenase 2 56 decitabine 56 sustained virological response 56 clinicopathological 56 tissue microenvironment 56 HER3 56 RhoA 56 #F FDG 56 subependymal giant cell 56 rs# [001] 56 cervical carcinoma 56 gastric carcinoma 56 rs# [002] 56 dopamine receptor gene 56 intratumoral 56 papillary renal cell carcinoma 56 T1 weighted 56 CCyR 56 Immunohistochemical analysis 56 hip BMD 56 neutrophil count 56 BCR ABL 56 SNP rs# [001] 56 follicular NHL 56 cellularity 56 granulosa cell 56 CD4 + T lymphocytes 56 prostatic adenocarcinoma 56 IFN γ 56 B Cell Lymphoma 56 recurrent ovarian 56 surgically resectable 56 endometrial cancers 56 cervical intraepithelial neoplasia 56 LNCaP cells 56 epithelioid 56 androgen hormone 56 IFNg 56 inhibit vascular endothelial 56 hematopoietic cancers 56 EGF receptors 56 pancreatic islet 56 microsatellite instability 56 intratumoral injection 56 gastrointestinal stromal tumors GISTs 56 perioperatively 56 CLL SLL 56 M1 muscarinic 56 K#N 56 neovasculature 56 myelofibrosis polycythemia vera 56 colorectal adenoma 56 telomerase reverse transcriptase 56 renal fibrosis 56 neuroblastoma tumors 56 invasive carcinomas 56 paclitaxel Taxol ® 56 steroidogenic 56 ER CHOP 56 constitutively 56 suppresses tumor 56 serum concentrations 56 methylenetetrahydrofolate reductase 56 gastrointestinal stromal tumor GIST 56 TTF Therapy 56 overexpressing 56 rs# [004] 56 delta isoform 56 mTOR inhibitors 56 lesional 56 multivariate adjustment 56 alfa 2a 56 macroalbuminuria 56 SCr 56 % CI #.#-#.# [005] 56 bronchoalveolar lavage 56 tyrosine kinase 56 cetuximab Erbitux ® 56 mutational status 56 leukocyte count 56 neoadjuvant therapy 56 hormone refractory 56 Tubulin 56 Aptivus ® 56 MALT lymphoma 56 urothelial 56 ovarian pancreatic 56 mitogen activated protein kinase 56 LTB4 56 neoplasia CIN 56 breast pancreatic 56 TGF alpha 56 nonmelanoma skin cancers 56 tTG 56 mitogenic 56 refractory colorectal cancer 56 endothelin receptor 56 pro apoptotic 56 Aromatase 56 oblimersen 56 Smac mimetic 56 retinoic acid receptor 56 neurofibromas 56 endometrial carcinoma 56 K ras mutation 56 pancreatic colon 56 sarcosine 56 Treg cell 56 receptor tyrosine kinase inhibitor 56 trastuzumab Herceptin 56 IgG4 56 SATB1 56 HOMA IR 56 RANTES 56 P = .# 56 melanocyte 56 CD# + [002] 56 lymphoid cells 56 serum urate 56 cagA 56 skeletal myoblasts 56 tumor necrosis 56 histologies 56 hormone therapy estrogen 56 corticosteroid dexamethasone 56 response pCR 56 skeletal metastases 56 inhibitory receptor 56 MGMT gene 56 intercellular adhesion molecule 56 oncoproteins 56 apolipoproteins 56 ACR# responses 56 Vandetanib 56 parathyroid carcinoma 56 cytotoxic therapy 56 5 HT2B receptor 56 DLBCL 56 lytic 56 situ LCIS 56 PPARg 56 neuroendocrine carcinoma 56 Fludara 56 NY ESO 56 selectively binds 56 lung metastasis 56 Alanine 56 Sensitivity specificity 56 tumor subtype 56 tumors 56 ouabain 56 Alessandro Riva 56 Kinoid 56 BCG refractory 56 null mice 56 inverse agonist 56 HuR 56 transduced 56 MAGE A3 ASCI 56 protein tyrosine phosphatase 56 E#F# 56 pleiotropic 56 leukemic cell 56 cathepsin B 56 adalimumab Humira 56 SGOT 56 serum PSA 56 cisplatin chemotherapy 56 basal cell skin 56 extracellular domain 56 imatinib resistance 56 micronuclei 56 TGF b 56 beta adrenergic receptors 56 dose dexamethasone 56 receptor subtype 56 GBM tumors 56 Basal cell 56 Stat5 56 LV dysfunction 56 Rap1 56 follicular lymphomas 56 eotaxin 56 Catenin 56 abacavir lamivudine 56 unmethylated DNA 56 metastatic lesions 56 antiapoptotic 56 lung carcinomas 56 refractory AML 56 macrophage colony stimulating 56 ductal cancer 56 Elevated serum 56 PARP inhibitor 56 maternal serum 56 Hypoxia Inducible Factor 56 PBMCs 56 elevated transaminases 56 paragangliomas 56 glutamic acid decarboxylase 56 protein tyrosine kinase 56 potent antiproliferative 56 prostate specific 56 receiving VICTRELIS 56 EGFR inhibition 56 ABL1 56 prognostic factors 56 effector memory 56 PTEN gene 56 cediranib 55 premalignant lesions 55 multivariate analyzes 55 polycythemia vera essential thrombocythemia 55 hypermethylation 55 Vidaza ® 55 deCODE BreastCancer 55 paclitaxel Taxol 55 transiently transfected 55 PC# cells 55 immunohistochemical 55 c Fos 55 Response Evaluation Criteria 55 Subtype 55 pancreatic ductal 55 platelet aggregation 55 anti CD3 55 inhibit replication 55 dutasteride 55 D dimer 55 serotonin receptor 55 astrocytomas 55 annexin V 55 trastuzumab Herceptin ® 55 leiomyoma